Monthly summary - February 2024

The positive momentum persisted into February, traditionally a challenging month for markets. Contrary to expectations, stock prices increased despite rising bond yields, catching many investors by surprise. Again, the US mega caps dominated trading and performance attribution with, for example, chipmaker Nvidia rallying after a stellar report to become the third company ever to reach a market cap of USD 2 trillion. Indeed, as the month progressed, the positive sentiment spread wider, reaching more sectors and even small and mid-cap stocks.

Investors ignored the delayed rate cuts

Better-than-expected economic data plus strong corporate earnings especially in the US, meant that investors overlooked the apparent postponing of central bank rate cuts. Going back to late last year, most investment banks envisioned cuts occurring already in March of this year. However, inflation numbers released in February dampened those expectations, pushing possible dates back to May or even later in the summer. Additionally, even though still an outlier opinion, some analysts said that the economy (again especially in the US) was so strong that cuts, if any, would happen even further into the future.

Choosing between a healthy economy and thus earnings growth, or lowered rates, it was obvious that investors favored the former, at least as long as the price of money was stable and expected to ultimately fall.

Worsened geopolitical situation

Geopolitical tensions worsened in February. In Ukraine, Russian forces took the town of Avdiivka in Donetsk after a long siege, making the Ukrainian army, who were outnumbered and in dire need of more western support, to retreat. French president, Emmanuel Macron, suggested that western troops at some point could be deployed in Ukraine, a statement which was seen as an escalation by the Kremlin.

Also, the war in Gaza continued unabated with Israeli forces moving further down towards the southern part of the strip, prompting increased criticism from governments and citizens around the world. Despite Israel being urged to halt the fighting, prospects for a cease-fire were still distant, even though negotiations continued. Leaders of Hamas in Gaza and Fatah in the West Bank assembled in Moscow to try to forge a common stance against Israel.

Local measures bolstered Chinese markets

Having underperformed the world equity indices for years, Chinese stocks rallied in February after the authorities introduced several measures to bolster the market, including a ban on short selling and certain quant strategies.

In Japan, the world’s best performing major market so far this year, the benchmark index finally surpassed its all-time high reached back in 1989.

Fourth consecutive monthly rise for the world index

The strong start to 2024 thus continued in February and the world index rose for a fourth consecutive month, albeit again with differences depending on investors’ base currency. Apart from utilities, all global sectors rose, led by consumer discretionary and information technology, while consumer staples and energy trailed the market. The same went for the regions, with Hong Kong and Nasdaq at the forefront while Europe lagged the world index.

 

OUTLOOK

In February, the market experienced further expansion where an increased number of stocks participated. Particularly, the biotechnology sector, measured as XBI, showed a strong upward trend given a long phase of consolidation. Recent data indicate strong healthcare productivity. February underlined the potential for 2024 to be a strong year for the healthcare sector.

Stock markets compensated by economic growth

Inflation is not on its way down as quickly as some had hoped but the economy is growing rapidly which compensates stock markets, and risk appetite is increasing. Europe is still behind, but our estimation is that it is only a matter of time before Europe turns around too.

The consumer price index in the US indicates continued rising housing costs but much of this appears to be built in lags and seasonal patterns. If housing costs rise more slowly in the spring, the US central bank (the Fed) will be close to its target and can start lowering interest rates. Our assessment is that the American stock market should remain strong if investors continue to believe that rates will come down in the summer at the latest, and if the first quarter’s reports in April-May show that the strong economy has provided decent profit growth. A possible weakening of the labor market during the spring could create new concerns about the economy, however we do not see strong signs of this today.

Optimistic sentiment

A series of data and phenomena can still go wrong, but the current optimism is fairly well anchored in profits, macro- and stock market statistics. The healthcare sector is generally strong and has the necessary prerequisites to deliver in 2024. Insurance is really the only area where, at present, there is broader uncertainty. The sector has undeniably started the year strongly and, as previously stated, the conditions exist for it to continue doing so during the year ahead. The proof is in the pudding.

 

More articles

All

Direkt

Finwire

Uncategorized

Rhenman & Partners

Monthly comment (Apr 25): Healthcare sector impacted by political uncertainty

Monthly summary – March 2025: a volatile month, again impacted by the macro-economic and political backdrop

Rhenman Healthcare Equity L/S minskade 13,61 procent i mars – volatilt för hälsovårdssektorn

Monthly summary – February 2025: Sentiment turned sour in February

Rhenman Healthcare Equity L/S sjönk 4,52 procent i februari – politisk osäkerhet pressade marknaden

Rhenman & Partners strengthens its Operations Team

Rhenman & Partners förstärker sitt Operationsteam

Monthly comment – January 2025: All sectors except technology closing in positive territory

Rhenman Healthcare Equity L/S ökade 8,41 procent i januari – stark rotation mot hälsovård

Monthly comment – December 2024

Rhenman Healthcare Equity L/S minskade 10,48 procent i december – tungt avslut på 2024

Monthly summary – November 2024: Once the election results were in, focus shifted torwards likely economic implications

Rhenman Healthcare Equity L/S ökade 1,67 procent i november – volatilt efter valet i USA

How is the healthcare sector affected by the US election results?

Hur påverkas en av världens mest reglerade sektorer av valutgången i USA?

Rhenman Healthcare Equity L/S minskade 2,00 procent i oktober – fokus på rapportperiod och USA-val

October 2024 summary – Initital focus on the earnings season switched to focus on election outcomes

Rhenman Healthcare Equity L/S föll 3,53 procent i september – positiv långsiktig utsikt trots volatil marknad

Monthly summary – September 2024

Rhenman & Partners strengthens its Investor Relations team further

Rhenman & Partners förstärker sitt Investor Relations-team ytterligare

Monthly summary – August 2024

Rhenman Healthcare Equity L/S ökade 3,35 procent i augusti – optimistisk syn på andra halvåret

Rhenman & Partners förstärker investeringsteamet – ytterligare en portföljförvaltare inom biopharma

Rhenman & Partners strengthens investment team – hires additional biopharma PM

Rhenman Healthcare Equity L/S ökade 5,26 procent i juli – tydlig sektorrotation

Monthly update – July 2024

Rhenman Healthcare Equity L/S ökade 1,42 procent i juni – stark månad för aktiemarknaden

Monthly summary – June 2024

Rhenman & Partners celebrates 15 years

Rhenman Healthcare Equity L/S föll 1,29 procent i maj – ser positivt på andra halvåret

Monthly summary – May 2024

Rhenman Healthcare Equity L/S minskade 2,57 procent i april – svag utveckling för de flesta delsektorer

Monthly summary – April

Rhenman Healthcare Equity L/S ökade 5,86 procent i mars – starka bidrag från medicinteknik

Monthly summary – March 2024

Rhenman & Partners strengthens its investor relations team

Rhenman & Partners förstärker Investor Relations

Rhenman Healthcare Equity L/S ökade 4,45 procent i februari – stark månad för bioteknik

Rhenman Healthcare Equity ökade 6,17 procent i januari – Shockwave och Eli Lilly bidrog positivt

Monthly summary – January 2024

Monthly summary – December 2023

Rhenman Healthcare Equity L/S ökade 5,43 procent i december – Cytokinetics bidrog positivt till utvecklingen

Monthly summary – November 2023

Monthly update – November 2023

Rhenman Healthcare Equity ökade 3,58 procent i november – Immunogen bidrog positivt

Monthly summary – October

Rhenman Healthcare Equity minskade 3,03 procent i oktober – två uppköp under månaden

The complex reality of investing in Biopharma

Rhenman Healthcare Equity minskade 6,07 procent i september – Immunovant steg kraftigt efter goda resultat

Monthly summary – September

Rhenman Healthcare Equity ökade 2,91 procent i augusti – Eli Lilly och Novo Nordisk i blickfånget

MONTHLY SUMMARY – AUGUST 2023

Rhenman Healthcare Equity minskade 4,01 procent i juli – Apellis Pharmaceuticals tyngde utvecklingen

Rhenman Healthcare Equity L/S ökade 2,65 procent i juni – ökar allokeringen mot tryggare bolag

Monthly summary – June 2023

Susanna Urdmark lämnar Rhenman & Partners

Susanna Urdmark to leave Rhenman & Partners

Susanna Urdmark lämnar Rhenman & Partners

Rhenman Healthcare Equity ökade 3,24 procent i maj – Immunogen bidrog positivt till utvecklingen

Dan Hoflund ny styrelseledamot för Rhenman & Partners Asset Management

Rhenman Healthcare Equity L/S ökade 3,83 procent i april – Tenet Health utvecklades starkt

Monthly summary – April 2023

Rhenman Healthcare Equity L/S minskade 1,02 procent i mars – Novo Nordisk aktiekurs fortsätter stiga

Monthly summary – March 2023

Lars Wedenborn ny styrelseledamot för Rhenman & Partners Asset Management

Lars Wedenborn – ny styrelseledamot Rhenman & Partners Asset Management

Rhenman Healthcare Equity L/S minskade 4,42 procent i februari – rekyl på aktiemarknaderna under februari

Monthly summary – February 2023

Rhenman Healthcare Equity ökade 3,75 procent i januari – Revance Therapeutics och Tenet Healthcare bidrog positivt (uppdatering)

Rhenman Healthcare Equity ökade 3,75 procent i januari – Revance Therapeutics och Tenet Healthcare bidrog positivt

Monthly summary – January 2023

Rhenman Healthcare Equity minskade 4,76 procent i december – Horizon Therapeutics främsta bidragsgivare

Monthly summary – December 2022

Rhenman & Partners strengthens its investment team with a biopharma analyst

Rhenman & Partners förstärker sitt investeringsteam med biopharmananlytiker

Rhenman Healthcare Equity L/S ökade 2,51 procent i november – Abiomed och Horizon Health bidrog positivt

Summary – November 2022

Rhenman Healthcare Equity L/S: +5,7% i oktober, flera faktorer pekar på hyfsad vinter men makrorisker ska ej underskattas – förvaltare

Summary – October 2022

Rhenman Healthcare Equity L/S ökade 5,68 procent i oktober – lyfter fram potentiell presidentcykeleffekt

Rhenman Healthcare Equity L/S: -1,5% i september, investmentbanker sänkte Jazz Pharmaceuticals och Vitrolife (R)

Rhenman Healthcare Equity L/S minskade 1,5 procent i september – Revance Therapeutics och Regeneron Pharmaceuticals främsta bidragsgivare

Teresa Isele ny vd för Rhenman & Partners Asset Management

Teresa Isele ny VD för Rhenman & Partners Asset Management AB

Teresa Isele to be the new CEO of Rhenman & Partners Asset Management AB

Rhenman Healthcare Equity L/S: +1,7% i augusti, förvaltare positiva till amerikansk läkemedelsreform

Rhenman Healthcare Equity L/S ökade 1,70 procent i augusti – biotekniksektorn gynnade utvecklingen

Rhenman Healthcare Equity L/S RC1 SEK: +5,4% i juli, ser på uppgångarna med försiktighet

Rhenman Healthcare Equity L/S ökade 5,39 procent i juli – fortsatt försiktig inställning

Rhenman Healthcare Equity L/S: +4,5% i juni, ser inte läge att öka aktieexponering trots viss ljusning.

Rhenman Healthcare Equity L/S ökade 4,50 procent i juni – stark återhämtning från små- och medelstora bioteknikbolag

Rhenman Healthcare Equity L/S minskade 3,19 procent i maj – stora läkemedelsbolag bidrog positivt

RHENMAN HEALTHCARE EQUITY L/S: -3,2% I MAJ, BUD PÅ BIOHAVEN

Rhenman & Partners fortsätter att expandera – sök rollen som biopharma-analytiker

Rhenman & Partners winner of Refinitiv Lipper Fund Awards Nordics

Rhenman & Partners vinnare av internationellt fondpris

Lediga tjänster inom Investor Relations

Rhenman Healthcare Equity L/S: -4,9% i april, tyngdpunkt på stora bolag för tillfället

Rhenman Healthcare Equity L/S minskade 4,93 procent i april – läkemedelsbolag minst påverkade av ökad global osäkerhet

EN